Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF

Fig. 1

Workflow for gene expression analysis with identification and validation of candidate biomarkers. Gastric cancer cell lines were treated with EGF, cetuximab, EGF plus cetuximab, trastuzumab, afatinib or trastuzumab plus afatinib. The classification of cell lines into responders and non-responders was carried out previously: MKN1 cells were responsive to cetuximab treatment, Hs746T cells were non-responsive [16, 19]. NCI-N87 cells were trastuzumab-responsive, MKN7 and MKN1 cells were non-responsive. NCI-N87, MKN1 and MKN7 cells were afatinib-responsive, Hs746T cells were non-responsive [17]. Regulated genes and biomarker candidates were identified following gene expression analysis. Biomarker candidates were validated in cell culture or clinical specimens

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us